Here are three things to know:
1. Peptilogics is a development stage biotechnology company developing antibiotics with a novel mechanism of action derived from their engineered cationic antibiotic peptide platform for the treatment of multidrug-resistant infections.
2. QIDP designation incentivizes the development of new antibiotics by including an additional five years of market exclusivity and eligibility for Priority Review and Fast Track designation.
3. According to Peptilogics CEO Sanjay Kakkar, MD, by 2020 more than 65,000 patients with prosthetic joint implants will develop PJIs per year, resulting in over $1.6 billion in annual inpatient costs.
More articles on orthopedics:
Continental Who’s Who recognizes Dr. Kenneth Kaminski: 3 things to know
Orthopedic surgeon to know: Dr. Catherine Robertson of UC San Diego Health
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
